Organization Profile

You just read:

Alnylam Pharmaceuticals Receives Priority Review in Canada for Patisiran, an Investigational RNAi Therapeutic for the Treatment of Hereditary Transthyretin-mediated Amyloidosis (hATTR amyloidosis) with Polyneuropathy

News provided by

Alnylam Pharmaceuticals, Inc.

Sep 24, 2018, 08:00 ET